欧美一区二区三区四区视频_91视频免费_1级黄色片_国产精品入口久久_久久人人爽人人爽人人片av高清_香蕉视频在线免费看_儿媳妇对老公父亲的称呼_麻豆一级片_91性高潮久久久久久久_国产h在线_99国产精品久久久久久久_伊在线久久丫_国产在线一区不卡_日韩av在线电影_日韩两性视频

SHANGHAI – January 5, 2022  Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun recruitment for its second Phase 1 clinical trial of topical TDM-105795 in patients with Androgenetic Alopecia (AGA). This follows successful completion of a single dose escalation study (NCT04913519), in which no material clinical safety issues were demonstrated based on reporting of adverse events, local skin reactions and changes from baseline in vital signs, safety labs, and ECG.

This second clinical trial is a 28-day multiple dose escalation study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia”. Its objectives are to evaluate topical TDM-105795 repeated dose safety and toleration and its pharmacokinetics, in order to define formulation strength(s) appropriate for a proof-of-concept Phase 2 study planned to follow.